文献速递母胎医学产科

颈项透明层3.0-3.4mm胎儿的染色体与遗传异常:系统综述与荟萃分析

Chromosomal and genetic anomalies in fetuses with nuchal translucency between 3.0 and 3.4 mm: A systematic review and meta‐analysis
RSS 订阅 · Acta Obstetricia et Gynecologica Scandinavica · 2026-10-26

该系统综述与荟萃分析纳入17项研究共7007例颈项透明层(NT)3.0-3.4mm的胎儿,旨在报告染色体异常患病率并评估侵入性产前诊断相对于cfDNA的增量收益。结果显示染色体异常率为13.1%(95%CI 9.3-17.3),其中21三体8.0%、18三体1.0%、13三体0.52%,致病性CNV为2.5%,单基因病为5.7%;孤立性NT者染色体异常率为12.4%。大多数异常可能通过cfDNA检测发现。

要点

  • NT 3.0-3.4mm胎儿染色体异常率13.1%,21三体占8.0%。
  • 致病性CNV检出率2.5%,单基因病(NGS/WES)检出率5.7%。
  • 孤立性NT 3.0-3.4mm者染色体异常率仍达12.4%。

核心结论

  • NT在3.0-3.4mm的胎儿染色体异常和拷贝数变异发生率高,多数可能通过cfDNA检测发现。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane Library,纳入17项研究共7007例NT 3.0-3.4mm的胎儿。
  • 纳入标准为NT 3.0-3.4mm且接受产前侵入性检测或产后遗传学评估的胎儿。
  • 采用随机效应模型的比率荟萃分析。

主要发现

  • NT 3.0-3.4mm胎儿染色体异常率为13.1%(95%CI 9.3-17.3)。
  • 常见三体:21三体8.0%(95%CI 5.1-11.5)、18三体1.0%(95%CI 0.6-1.7)、13三体0.52%(95%CI 0.2-1.0)。
  • 性染色体异常0.58%(95%CI 0.4-0.8),罕见常染色体三体0.27%(95%CI 0.1-0.6)。
  • 致病性或可能致病性CNV(CMA检测)为2.5%(95%CI 1.3-3.9)。
  • NGS/WES检测的单基因病为5.7%(95%CI 3.3-8);孤立性NT 3.0-3.4mm者染色体异常率为12.4%(95%CI 7.9-17.7)。

关键数值与推荐

  • NT 3.0-3.4mm胎儿染色体异常率13.1%(95%CI 9.3-17.3)。
  • 21三体8.0%(95%CI 5.1-11.5),18三体1.0%(95%CI 0.6-1.7),13三体0.52%(95%CI 0.2-1.0)。
  • 性染色体异常0.58%(95%CI 0.4-0.8),罕见常染色体三体0.27%(95%CI 0.1-0.6)。
  • 致病性/可能致病性CNV 2.5%(95%CI 1.3-3.9),单基因病5.7%(95%CI 3.3-8)。
  • 孤立性NT 3.0-3.4mm者染色体异常率12.4%(95%CI 7.9-17.7)。

临床怎么用

  • 对NT 3.0-3.4mm的胎儿应告知染色体异常和CNV风险增高,可考虑cfDNA作为筛查选项。
  • cfDNA可能检出大多数异常,但侵入性诊断可额外发现CNV和单基因病。
  • 孤立性NT 3.0-3.4mm者仍存在较高染色体异常风险,不应忽视。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fetuses with a nuchal translucency between 3.0 and 3.4 mm showed a high rate of chromosomal anomalies and copy number variants, most of which could potentially be detected through cell-free DNA. Abstract Introduction To report the prevalence of chromosomal anomalies in fetuses with a nuchal translucency (NT) between 3.0 and 3.4 mm and to assess the incremental yield of invasive prenatal diagnosis over cell-free DNA (cfDNA) in these fetuses. Material and Methods MEDLINE, EMBASE, and The Cochrane Library were searched. Inclusion criteria encompassed fetuses with an NT between 3.0 and 3.4 mm undergoing prenatal invasive testing or postnatal genetic assessment. The observed outcomes included common trisomies such as Trisomy 21, 18, and 13, sex chromosomal anomalies (SCAs), rare autosomal anomalies, copy number variants detected by chromosomal microarray (CMA), and single-gene disorders. We also reported the rate of anomalies potentially detectable by cfDNA. Finally, we planned to perform a subgroup analysis involving cases with isolated NT between 3.0 and 3.4 mm, including only cases undergoing detailed first-trimester ultrasound assessment. A random-effects meta-analysis of proportions was utilized to analyze the data. Results Seventeen studies (7007 fetuses) were included. In fetuses with NT measurements between 3.0 and 3.4 mm, chromosomal anomalies were identified in 13.1% (95% CI 9.3–17.3). Common trisomies included Trisomy 21 at 8.0% (95% CI 5.1–11.5), Trisomy 18 at 1.0% (95% CI 0.6–1.7), and Trisomy 13 at 0.52% (95% CI 0.2–1.0) of all chromosomal anomalies. SCAs occurred in 0.58% (95% CI 0.4–0.8), while rare autosomal trisomies and pathogenic or likely pathogenic copy number variants (CNVs) were found in 0.27% (95% CI 0.1–0.6) and 2.5% (95% CI 1.3–3.9), respectively. Additionally, single-gene disorders detected via NGS/WES were reported in 5.7% (95% CI 3.3–8) of cases with NT between 3.0 and 3.4 mm. When examining only fetuses with an isolated NT between 3.0 and 3.4 mm, all chromosomal anomalies were identified in 12.4% (95% CI 7.9–17.7). Conclusions Fetuses with an NT between 3.0 and 3.4 mm showed a high rate of chromosomal anomalies and CNVs, most of which could potentially be detected through cfDNA.

来源:Acta Obstetricia et Gynecologica Scandinavica,查看原文。版权归原作者所有。

引用

  1. Acta Obstetricia et Gynecologica Scandinavica:Chromosomal and genetic anomalies in fetuses with nuchal translucency between 3.0 and 3.4 mm: A systematic review and meta‐analysis

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。